Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026Completed underwritten offering of Series A Common S
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sagimet Biosciences (NASDAQ:SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China. The company also outlined plans fo
Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.
Sagimet dips after Ascletis posts 52-week phase 3 open-label extension denifanstat acne data. Read more here.
Sagimet Biosciences (SGMT) closed an offering of nearly 8.8 million series A common shares at $10 ap
Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $27.85, according t
Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.
Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks.
Sagimet Biosciences (SGMT) priced an offering of about 8.8 million shares of series A common stock a
Detailed price information for Neogen Corp (NEOG-Q) from The Globe and Mail including charting and trades.
On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 […]
United Therapeutics (UTHR) stock and Sagimet Biosciences (SGMT) stock slip as Goldman Sachs issued Sell ratings on the companies. Read more here.
Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.33, according t
Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.33, according t
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here).H.C. Wainwright 28th Annual Global Investment Conf
Sagimet Biosciences (SGMT) said Tuesday that it expects to begin enrolling patients in Q4 for the US
This is the newest page. Registered accounts read further back.